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ABSTRACT Previous studies showed that binding of water-soluble phosphatidylserine (C6PS) to bovine factor Xa (FXa) leads
to Ca2þ-dependent dimerization in solution. We report the effects of Ca2þ, C6PS, and dimerization on the activity and structure of
human and bovine FXa. Both human and bovine dimers are 106- to 107-fold less active toward prothrombin than the monomer,
with the decrease being attributed mainly to a substantial decrease in kcat. Dimerization appears not to block the active site, since
amidolytic activity toward a synthetic substrate is largely unaffected. Circular dichroism reveals a substantial change in tertiary or
quaternary structure with a concomitant decrease in a-helix upon dimerization. Mass spectrometry identiﬁes a lysine (K270) in the
catalytic domain that appears to be buried at the dimer interface and is part of a synthetic peptide sequence reported to interfere
with factor Va (FVa) binding. C6PS binding exposes K351 (part of a reported FVa binding region), K242 (adjacent to the catalytic
triad), and K420 (part of a substrate exosite). We interpret our results to mean that C6PS-induced dimerization produces substan-
tial conformational changes or domain rearrangements such that structural data on PS-activated FXa is required to understand
the structure of the FXa dimer or the FXa-FVa complex.INTRODUCTION
The process of blood clotting and the subsequent dissolution
of the clot, are crucial events in controlling the normal flow
of blood after vascular injury. The blood coagulation system
consists of several consecutive reactions, in which activation
of one zymogen leads to the activation of another. This
sequential nature results in small initial signals being ampli-
fied significantly to produce first a platelet plug and then
a hardened clot. It is essential that each step in the process
be carefully regulated. Platelet activation is a major regula-
tory event in human blood coagulation. The platelet
membrane contains phosphatidylserine (PS) mainly in its
cytoplasmic leaflet (1), but this asymmetric arrangement of
PS is lost upon platelet activation (2). It is now widely
accepted that a PS-containing membrane is required for the
activity of two complexes that are key to thrombin forma-
tion, the factor-X-activating complex (Xase) and the
prothrombin-activating complex (prothrombinase). The
conversion of prothrombin (II) to thrombin (IIa) is a vital
step in the blood coagulation process. When thrombin
production is not properly regulated and localized to
membranes at the site of tissue damage, thrombotic disease
such as stroke and heart attack can result. The prothrombi-
nase complex functions on platelet membranes, is positioned
metabolically at the intersection of the intrinsic and extrinsic
paths of the traditional ‘‘coagulation cascade’’, and consists
of a serine protease, factor Xa, and its associated cofactor,
factor Va (3,4). Thrombin is a central metabolite of blood
coagulation (5) and has a key role in amplifying the response
to injury since it activates additional platelets that trigger
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This amplification mechanism leads to the hypothesis that
inhibition of factor Xa (FXa) may be more efficient than
inhibition of thrombin (6,7). In addition, it is anticipated
that specific FXa inhibitors would prevent thrombus forma-
tion without compromising hemostasis, thus providing
a better efficacy profile (7). This qualifies FXa as an attrac-
tive target for the development of new antithrombotic drugs
(8). A recent report suggests that inhibiting factor Xa is
effective in preventing both arterial and venous thrombosis
(9).
The domain organization of factor Xa (FXa) is similar
to that of its substrate, prothrombin. Both proteins have an
N-terminusg-carboxyglutamic acid-rich regionGLAmodule
essential for membrane binding, two Cys-rich highly folded
domains, (epidermal-growth-factor (EGF)-like cassettes
EGFN and EGFC in FXa and Kringle domains k1 and k2
in prothrombin), and a catalytic domain containing the cata-
lytic triad (H/D/S) in the substrate binding site, and, in the
case of FXa, factor Va interaction sites (10–12). Factor X
consists of two peptides, with the membrane-binding portion
(GLA-EGFNC) attached by an S-S bond to the catalytic
domain. Activation of FX to FXa involves cleavage of a
single small peptide from the N-terminus of the catalytic
chain. Activation of prothrombin to thrombin by FXa
involves proteolysis of two peptide bonds, Arg273-Thr274
between the EGFC module and the catalytic domain and
Arg322-Ile323 within the catalytic domain (13).
Our studies show that PS acts as an allosteric regulator of
both factors Xa and Va, and their substrate prothrombin. To
demonstrate this, we introduced the use of a soluble lipid,
1,2-dicaproyl-sn-glycero-3-phospho-L-serine (C6PS), that
does not occur in human physiology, but is a powerful tool
that allows us to examine the details of PS binding to
doi: 10.1016/j.bpj.2008.10.013
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nearly impossible to accomplish for proteins bound to
amembrane surface.Using this, we showed that FXa has three
C6PS binding sites, one in the GLA domain that binds C6PS
only in the absence of Ca2þ, one Ca2þ-requiring binding site
in the EGFNC domain pair (C6PS binding to this site regulates
activity), and a Ca2þ-dependent site in the catalytic domain
(not a lipid-regulatory site and likely part of a protein recog-
nition site) (14). Functional response to C6PS binding to the
EGFNC site requires linkage of the GLA, EGFNC, and cata-
lytic domains in the presence of Ca2þ (14) and is specific
for PS (15). Binding to this site increases the rate of
prothrombin activation by human FXa, changes the order in
which human factor Xa catalyzes cleavage of the two peptide
bonds in prothrombin (16), produces structural changes in
bovine FXa as judged by intrinsic fluorescence and circular
dichroism (CD) (14), and triggers bovine FXa dimer forma-
tion in a Ca2þ-dependent fashion (17).
It has long been known thatmany enzymes undergo ligand-
triggered oligomerization (18), and it has been estimated that
as many as 15% of all enzymes fall into this category (19–22).
Thus, ligand-triggered oligomer formation is often a regula-
tory mechanism (19). In some cases, the monomer is active
and the oligomer is inactive (e.g., carbamoyl phosphate syn-
thase forms inactive dimers in response to N-acety-glutamic
acid binding), whereas in other cases, the oligomer is active
(e.g., a threonine deaminase inactive dimer forms an active
tetramer in response to AMP binding) (19). This and the crit-
ical role of both platelet membranes and FXa in human blood
coagulation led us to ask whether our observations with
bovine FXamight extend to human FXa, specifically whether
this key human enzyme might also dimerize upon binding
C6PS? In addition, we asked whether PS-induced bovine or
human FXa dimer is more or less active than the monomer?
Two modes of enzyme regulation by ligand-induced multi-
merization have been proposed: occlusion of substrate
binding because of formation of a multimer interface or alter-
ation of the active site by conformational changes induced by
multimer formation (19). If FXa activity is altered in the PS-
induced dimer, is this because dimerization alters the active
site or substrate binding to the FXa enzyme? Finally,
prothrombin undergoes large PS-triggered structural changes
and domain reorganizations (23,24). A model of FXa based
on x-ray structures (25) puts the active site 89 A˚ from the
plane of Ca2þ ions that define the membrane-protein inter-
face. Fluorescence measurements put the active site 61 A˚
above the surface of a PS-containing membrane (26), sug-
gesting similar PS-induced structural reorganization in FXa.
If such changes occur, any predictions about the structure
of the FXa dimer or the FXa-FVa complex from crystallo-
graphic data obtained in the absence of PS would be unreli-
able. Thus, we askwhether structurally sensitive observations
on FXa in a C6PS-triggered dimer are consistent with models
of FXa structure obtained from x-ray diffraction in the
absence of C6PS?In this work, we report that human FXa indeed forms
a dimer. As for bovine FXa, dimerization is sensitive to
Ca2þ concentration. Second, we show that the proteolytic
enzyme activities of both human and bovine FXa toward
prothrombin are greatly reduced due to a substantial decrease
in kcat and a slight increase in KM. However, activity toward
a tripeptide synthetic substrate does not decrease in the
dimer. These results suggest that the activity of the dimer
is lowered due not to occlusion of the active site but rather
to conformational changes or occlusion of substrate exosites.
Finally, C6PS-induced dimer formation is also accompanied
by a slight decrease in helical secondary structure but
a substantial change in tertiary or quaternary structure. In
addition, mass spectrometry and chemical modification of
exposed lysines identified residues whose exposure to
solvent was altered by Ca2þ and C6PS binding as well as
dimer formation. We found that dimer models based on
current crystallographic models of monomeric FXa were
not consistent with these and other experimental observa-
tions. We conclude that PS-induced dimerization of human
FXa significantly alters its structure and inhibits its activity,
although additional work is needed to determine the extent
to which this phenomenon might occur on membranes and
thus have significance in the regulation of FXa during
blood coagulation.
EXPERIMENTAL PROCEDURES
Materials
C6PS in the form of sodium salt was purchased from Avanti Polar Lipids
(Birmingham, AL). The FXa-specific substrate N-2-benzyloxycarbonyl-D-
arginyl-L-arginine p-nitroanilide dihydrochloride (S-2765) and IIa-specific
substrate H-D-phenylalanyl-L-pipecolyl-L-arginine p-nitroanilide dihydro-
chloride (S-2238) were purchased from DiaPharma (West Chester, OH).
Human and bovine prothrombin and FXa were obtained from Hematologic
Technologies (Essex Junction, VT), as well as FXa labeled in its active site
with dansyl tripeptide choloromethyl ketone (DEGRXa). FXa was assayed
before use using an active-site titrated standard (27). All other chemicals
were ACS reagent grade; all solvents were high-performance liquid chroma-
tography (HPLC) grade. An Atlantis dC18 100 mm  100 mm column and
an Acquity trapping column 5 mm C18 180 mm  200 mm were purchased
from Waters (Milford, MA).
Short-chain phospholipid sample preparation
Chloroform was removed from measured amounts of C6PS stock using
a stream of nitrogen, and the lipid sample was dissolved in cyclohexane
and lyophilized overnight. The lyophilized lipid was then suspended in an
appropriate amount of water to reach a desired concentration. C6PS from
this stock was used within 1–2 days.
Native polyacrylamide gel electrophoresis
FXa or DEGR-Xa (250 nM in the buffer A: 50 mM Tris, 150 mM NaCl,
5 mM Ca2þ and 0.6% polyethylene glycol (PEG), pH 7.4) were incubated
at 23C for 5 min in the absence and presence of 400 mM C6PS, and then
were run togetherwith knownmarker proteins (116-14KDa,Sigma, St. Louis,
MO) on an 8%native polyacrylamide gel in a BioRadMini-Protean IIminigelBiophysical Journal 96(3) 974–986
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blue, as detailed previously (17,28).
Activity assay of factor Xa
The activity of factor Xa was checked using the synthetic chromogenic
substrate S-2765 in an assay (29) adapted to an SLT 340-ATTC microplate
reader (Tecan U.S., Hillsborough, NC).
Kinetics for thrombin appearance
The initial rates of prothrombin activation were obtained using the synthetic
substrate S-2238 to follow the appearance of thrombin activity. Details of
the method were described previously (30).
Effect of C6PS on factor Xa activity
The amidolytic activity of FXa in the presence of C6PS was determined
using a synthetic substrate, S-2765, specific for FXa active site, as described
previously (29).
Circular dichroism measurements
CD spectra were recorded from 260 to 200 nm on an Aviv Model 620S spec-
trometer (AvivAssociates, LakeWood,NJ) in a 1-cm path length cell at 25C
with a bandwidth of 1 nm. Samples were prepared in buffer B (1.2 mM Tris,
150 mM NaCl, pH 7.4). Details of the method are described elsewhere (14).
Modeling kinetic data
Proteolytic activity of FXa with prothrombin as substrate
Kinetic constants for the proteolytic activation of prothrombin were deter-
mined by following the time course of thrombin activity for various
prothrombin and FXa concentrations. Two types of analysis were carried
out. First, data obtained at each FXa concentration were analyzed using
a traditional Michaelis-Menten approach, with the use of the nonlinear
regression algorithm incorporated into SigmaPlot (Systat Software, San
Jose, CA). Because of FXa dimerization, the kinetic constants obtained at
different FXa concentrations were not in agreement. For this reason, we
carried out an analysis that took into account the presence of three FXa
species, FXa not bound to C6PS, and both FXa monomer and dimer bound
to C6PS. In this analysis, the observed rate (Robs) is expressed in terms of the
separate kinetic constants (kcat and KM) of the three forms, the fractions of
FXa present as unbound monomer (f0), C6PS-bound monomer (f1), and
C6PS-bound dimer (f2), the prothrombin concentration ([S]), and the total
FXa concentration ([Xa]tot):
Robs ¼

S
 k0cat  f0 ½Xatot
K0M þ

S


þ

S
 kmcat f1ð1 f0Þ½Xatot
KmM þ

S


þ

S
 kdcat 2 1 f0f2 ½Xatot
KdM þ

S


: (1)
The fraction of FXa bound to C6PS depends on the Kd
PS for C6PS binding
to the regulatory site of human FXa (705 10 mM (27); 865 5 mM (15)):
f0 ¼ ½Xatot
KPSd þ ½Xatot
: (2)
The fraction of C6PS-bound FXa present as dimer was previously shown
to be (17)Biophysical Journal 96(3) 974–986f2ð½XatotÞ ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1 þ 8 k 1 f0½Xatot
q
 1ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1 þ 8 k 1 f0½Xatot
q
þ 1
; (3)
where k ¼ 1Kd2 and Kd2 is the dimer dissociation constant. Using these
expressions, we then fitted globally the data obtained at all prothrombin
and FXa concentrations to obtain k0cat/K
0
M, k
m
cat and K
m
M, k
d
cat and K
d
M,
and k. It quickly became apparent that the unbound monomer contributed
almost nothing to the observed activity (~95% of FXa exists as C6PS-bound
species at 400 mM C6PS), so this species was eliminated to reduce the
number of free parameters and obtain more reliable parameter estimates.
Amidolytic activity of FXa on synthetic substrate
S-2765
These data were treated using the same formalism described under proteo-
lytic activity, except that each species was assigned only a single rate char-
acteristic of that species:
Robs ¼ R0  f0  ½Xatot þRm f1

1 f0

 ½Xatot þRd  2

1 f0

f2 ½Xatot: (4)
Acetylation and identiﬁcation of lysine residues
Solvent-exposed primary amines of FXa were acetylated as described (31).
Briefly, 700-nM aliquots of FXa in 100 mM phosphate buffer (pH 7.2)
were treated with a 1000-fold molar excess of acetic anhydride (Sigma Al-
drich)/amine residue (~16.8mM) for 30min at room temperature. Test condi-
tions included 3 mM Ca2þ, 3 mMCa2þ and 400 mMC6PS, 5 mM Ca2þ, and
5 mM Ca2þ and 400 mMC6PS. The pH was adjusted every 5 min using 5 M
NaOH tomaintain a pH>7.0. The reactionwas carried out under nondenatur-
ing conditions so as to retain the protein’s native structure. Finally, an equal
volume of 1MTris pH 8.0was added to quench any remaining unreacted ace-
tic anhydride.Under these conditions, solvent-exposed lysine residues should
be modified by the addition of an acetyl group. The modified FXa was then
purified by HPLC using a Hewlett Packard (Wilmington, DE) 1100 HPLC
system equipped with a C4 Vydac column (4.2 mm i.d., 5-mm particles).
Elutionwas carried out usingwater/0.1% trifluoroacetic acid (v/v) and a linear
gradient from 5% to 60% of acetonitrile/0.1% trifluoroacetic acid (v/v).
Fractions containing purified FXa, as determined by matrix-assisted laser
desorption/ionization mass spectrometry (MALDI-MS), were combined and
lyophilized. After lyophilization, FXa was resuspended in 50 mL of 50 mM
NH4HCO3, pH 7.8, and was then digested with trypsin (Promega Madison,
WI) and Glu-C (pH 8) (Roche, Indianapolis, IN) using a 1:20 E/S ratio.
Two proteases were used because trypsin activity is inhibited when a lysine
residue is acetylated.MALDI-MS and nanoLC-ESI-MS/MSwere performed
on the resulting peptides. For the mass spectrometric analysis we used
MALDI-TOF to look for the intact protein fractions after the HPLC separa-
tion. Afterward, the digested protein was analyzed by MALDI-TOF to deter-
mine the efficiency of the digestion and then the same mixture was subjected
to nano-LC-ESI-MS/MS to identify the specific lysine residues that were
acetylated. This was accomplished by comparing the mass spectra of the
FXa digest and modified FXa digest to identify acetylated peptides as those
that corresponded in mass to a predicted proteolytic fragment of FXa plus
the mass of one or more acetyl groups (þ42 Da). Acetylated peptides were
then analyzed by nano-LC-ESI-MS/MS to verify the peptide sequence and
confirm the site(s) of modification, thus identifying the acetylated residues.
MALDI-MS
Samples (0.5 mL) were spotted onto a 100 sample stainless steel MALDI
plate and mixed on target with 0.5 mL of a saturated solution of
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acid. Mass spectrometric analyses were then performed on an Applied Bio-
systems DE-STR MALDI-TOF mass spectrometer in the reflector positive
ion mode with a resolution of >10,000. The MS spectra were calibrated
externally using a mixture of standard peptides with a mass error of
%0.01%. Data were acquired using an accelerating voltage of 23,000 volts,
grid percentage of 65%, and delay time of 200 ns.
NanoLC-ESI MS/MS
NanoLC-ESI MS/MS mass spectrometry was performed on a Micromass
Q-Tof Premier mass spectrometer equipped with a NanoAcquity LC system
(Waters). Analyses were performed using a 3-mm Atlantis dC18 100 mm 
100 mm column with a flow rate of 300 nL/min and an Acquity trapping
column 5 mmC18 180 mm 200 mmwas used to clean up the sample before
injection into the analytical column for 3 min at 5 mL/min flow rate. Briefly,
a 2-mL aliquot of the digest sample was loaded onto the column. Peptides
were eluted using a linear gradient from 2% B (acetonitrile/0.1% formic
acid (v/v)) ramped to 95% B over 60 min. Instrument settings for MS anal-
yses included a capillary voltage of 3.5 kV, cone voltage of 30 V, and an
m/z range of 200–2000. MS/MS data were acquired using a data-dependent
acquisition method selecting collision energies based on mass and charge
state. For calibration, an external lock mass was used with a separate refer-
ence spray (LockSpray) using a solution of Glu-fibrinogen peptide
(300 fmol/ml) with a mass of 785.8496 (2þ ion) with errors of <20 ppm.
RESULTS
Human factor Xa forms a dimer in the presence
of soluble C6PS at 5 mM Caþ2
Bovine FXa dimerizes in the presence of 400 mM C6PS at
5mMCa2þ (17).We have previously demonstrated the ability
of nativegel electrophoresis to correctlymeasure both the pres-
ence andmolecular weight of bovine FXa dimer (17) and both
bovine and human FXa-FVa complex (16,32). This method is
based on the observation that the thermodynamics of protein
association reactions can be determined by gel analysis
(32,33), presumably because the local high concentrations of
proteins in the gel prevent complex dissociation at rates to be
expected in dilute solution. Thus, to confirm that human FXa
behaves similarly, native polyacrylamide (8%) gel electropho-
resis was performed on a sample of 250 nM human FXa
(Fig. 1, lane 1) in the presence of 400 mM C6PS and 5 mM
Ca2þ. A similar sample prepared in the absence of Ca2þ and
C6PS ran at almost half the molecular mass (Fig. 1, lane 4)
of this sample. When 250 nM DEGR-Xa was incubated in
the presence of C6PS and 5 mM Ca2þ, the band (Fig. 1, lane
3) corresponded to the molecular mass of monomer human
FXa with no dimer band detected. These results demonstrate,
first, that, like bovine FXa, human FXa dimerizes in the pres-
ence of 400 mM soluble C6PS and 5 mM Ca2þ and, second,
that labeling the active site of FXa inhibits dimer formation.
Effect of dimerization on FXa function
Proteolytic activity of factor Xa at high (5 mM) Ca2þ concen-
tration
Proteolytic activation of prothrombin (II) by both human and
bovine FXa was carried out in the presence of 400 mMC6PSusing a range of FXa concentrations (5–500 nM) and
prothrombin concentrations (0.25–1.5 mM). Initial rates of
prothrombin activation were obtained by linear regression
of early time courses. Fig. 2, A and B, portrays these data
in the traditional Michaelis-Menten format for human and
bovine FXa, respectively. These data were fitted using the
Michaelis-Menten formalism to obtain kcat/KM, kcat, and
KM for each FXa concentration examined. Fig. 3, A and B,
shows plots versus FXa concentration of the kinetic
constants (kcat/KM) for human and bovine FXa, respectively.
It is evident that the apparent kcat/KM decreased with
increasing FXa concentration, i.e., the enzyme’s catalytic
efficiency decreased dramatically and asymptotically with
its concentration. The insets in Fig. 3 show that the decrease
in kcat/KM is due primarily to a decrease in kcat (left vertical
axis), but also involves a small increase in KM (right vertical
axis). The observed variation of the apparent kinetic
constants with FXa concentration under conditions that are
known to trigger FXa dimerization suggests that the dimer
is significantly less active than the monomer. Approximate
values of kcat and KM for the monomer and dimer were taken
as values obtained at 50 nM and 500 nM FXa, respectively,
and are recorded in Table 1 as kcat
effect and KM
effect for 5 mM
Ca2þ. Next, the data were fit globally to the dimer model
described in Experimental Procedures (Eqs. 1–3) using five
data sets and only five parameter values: KM and kcat for
both monomer and dimer, and Kd2, with the fits shown as
lines in Fig. 2. The five data sets could not define all five
parameters uniquely, so an iterative fitting algorithm was
used. We began with values for KM
effect for both the dimer
and monomer and varied kcat for both species and Kd2. We
repeated this procedure with kcat fixed and then again with
KM fixed until the fits converged to invariant values of all
five parameters. It is clear that this model provides a reason-
able description of all five data sets. Fitting yielded dimer
FIGURE 1 Native polyacrylamide gel electrophoresis of human FXa in
the presence and absence of C6PS at 5 mM Ca2þ. A 250-nM sample of
FXa or DEGR-Xa was incubated with or without 400 mM C6PS at 23C
in buffer A containing 5 mM Ca2þ and then run on an 8% native polyacryl-
amide gel that also contains a saturating amount (400 mM) of C6PS. Lanes
1–4 contain, respectively, human FXa in the presence of 400 mM C6PS;
molecular weight markers; human DEGR-Xa in the presence of 400 mM
C6PS; and human FXa in the absence of C6PS.Biophysical Journal 96(3) 974–986
978 Chattopadhyay et al.dissociation constants (Kd2) of 14 5 1 nM for human FXa
and 14 5 1.5 nM for bovine FXa, as compared to a value
of 20 nM previously estimated from intrinsic fluorescence
data (17). This procedure yielded monomer kcat values of
4.05 0.4 103 s1 for human FXa and 35 5 103 s1
for bovine FXa. Values for the dimer were 2 5 1.6 
109 s1 and 8 5 1  109 s1 for human and bovine
FXa, respectively. KM values were 0.4 5 0.08 mM and
0.4 5 0.06 mM for monomer and 2.6 5 1.5 mM and
2.55 0.4 mM for dimer, for human and bovine FXa, respec-
tively. These values are listed in Table 1 as kcat
global and
KM
global for 5 mM Ca2þ. Earlier studies performed at low
FIGURE 2 Prothrombin activation as a function of prothrombin concen-
tration at different FXa concentrations and at 400 mMC6PS. The initial rates
of thrombin (IIa) formation are plotted as a function of prothrombin (II)
concentration. The appearance of thrombin was determined by the rate of
S-2238 hydrolysis at 37C (see Experimental Procedures). (A) Results for
human FXa at concentrations of 5 nM (solid circles), 10 nM (open circles),
25 nM (solid triangles), 50 nM (open triangles), 100 nM (solid squares),
200 nM (open squares), and 500 nM (solid diamonds). (B) Results for
bovine FXa at concentrations of 5 nM (solid squares), 10 nM (solid dia-
monds), 25 nM (open squares), 50 nM (open circles), 100 nM (solid circles),
200 nM (solid triangles), and 500 nM (open triangles). The reaction mixture
contained prothrombin at concentrations from 0.25 to 1.5 mM, FXa in
50 mM Tris, 175 nM NaCl, 0.6% poly(ethylene glycol), 5 mM Ca2þ, and
400 mM C6PS. The data for all FXa concentrations were fitted assuming
the Michaelis-Menten model for the rate of activation by each of three
species (Eqs. 1–4). The curves illustrate the success of the global fit. This
yielded estimates of the kcat and KM for the monomer and dimer and dimer
dissociation constants of 145 1 nM for human FXa and 14.25 1.5 nM for
bovine FXa.Biophysical Journal 96(3) 974–986concentrations of factor Xa (5 nM, i.e., monomer-forming
conditions) gave KM and kcat values for prothrombin activa-
tion of 0.3 5 0.01 mM and 3.9 5 0.1  103 s1, respec-
tively (16), which agree well with the values obtained here
for the FXa monomer. This analysis is therefore consistent
with the C6PS-bound FXa monomer being ~106- to 107-
fold more active than the dimer in the cases of both human
(kcat/KM of 10
4 5 3000 vs. 0.8 5 1  103 M1 s1) and
bovine (7500 5 9700 vs. 3 5 2  103 M1 s1) FXa.
We note that the second-order rate constants for the dimer
are so small that they are not distinguishable from zero,
and their exact numerical values should not be taken seri-
ously.
Effect of Ca2þ concentrations on factor Xa dimerization
The dimerization constant of bovine FXa is very sensitive to
Ca2þ concentration (17). To determine the dependence of the
human FXa dimerization constant on Ca2þ concentration, we
measured the initial rate of prothrombin activation as a func-
tion of FXa concentration (Fig. 4 A) at five Ca2þ
FIGURE 3 Michaelis-Menten rate constants for prothrombin activation as
a function of FXa concentration at 400 mM C6PS. Apparent second-order
rate constants, kcat/KM, for proteolytic reaction of prothrombin activation
are plotted as a function of FXa concentration of (A) human FXa and (B)
bovine FXa. Values of kcat and KM at each FXa concentration were obtained
by applying the Michaelis-Menten model to the individual curves in Fig. 2,
with their ratios plotted here. (Insets) Decrease of kcat (open squares, left
ordinate) and increase of KM (open triangles, right ordinate) with increasing
FXa concentration results in the observed decrease in kcat/KM. The error bars
derive from the uncertainty in the fitting parameters.
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þ2 concentrations
Ca2þ
concentration
(mM)
Xa monomer Xa dimer
kcat
effect kcat
global KM
effect KM
global kcat
effect kcat
global KM
effect KM
global
3 2.8  103
5 4.0  104
2.9  103
5 1.7  103
608.4
5 212.1
604.99
5 104.5
2.3  104
5 4.0  104
1.8  109
5 1.5  109
782.4
5 363.8
984.98
5 570.94
3.5 3.1  103
5 4.2  104
3.1  103
5 2.2  104
549.0
5 191.2
548.9
5 121.7
2.9  104
5 3.0  105
1.2  109
5 9.9  1010
843.7
5 209.6
1191.9
5 362.5
4 3.0  103
5 2.4  104
3.5  103
5 3.6  104
526.5
5144.4
509.9
5117.2
3.2  104
5 3.2  105
1.32  109
5 1.1  109
886.8
5 191.5
1499.9
5 1214.9
5 3.5  103
5 3.8  104
4.0  103
5 4.0  104
448.0
5 136.0
400.0
5 80.0
7.0  104
5 3.4  105
2.0  109
5 1.57  109
1791.0
5 154.0
2600.9
5 1500.0
6 4.3  103
5 2.8  104
3.8  103
5 3.0  104
420.4
5 85.2
449.9
5 187.2
5.6  104
5 1.2  105
1.7  109
5 1.0  1010
1942.8
5 680.06
1899.9
5 1259.2
Values of kcat
effect and KM
effect for Xa monomer and dimer were obtained for 5 and 500 nM FXa at each Ca2þ concentration (as seen in Fig. 2 and described
in Results). The kcat
global and KM
global values for monomer and dimer were obtained by the global fitting procedure using data from five FXa concentrations
and prothrombin concentrations (see Results and Eqs. 1–3). The kcat values are in s
1 and KM values in nM.concentrations (3, 3.5, 4, 5, and 6 mM) and fitted these data
to a simple dimerization model (Eq. 3), which gives the value
of dimer dissociation constants (Kd2) and kinetic constants
(kcat
global and KM
global for monomer and dimer in Table 1)
at each Ca2þ concentration. The Kd2 value is the inverse of
the dimerization constant (k) defined in Eq. 3, and the Kd2
values obtained in this way are plotted in Fig. 4 B (open
triangles) as a function of Ca2þ concentration. In addition,
the apparent kcat and KM for monomer and dimer were ob-
tained at each Ca2þ concentration from the Michaelis-
Menten plots at 5 and 500 nM FXa, respectively. These
are recorded in Table 1 as kcat
effect and KM
effect for each
Ca2þ concentration. Kd2 values obtained from the hyperbolic
plots in Fig. 4 A are plotted in Fig. 4 B (solid circles). The
Kd2 values obtained by both methods are quite similar. The
observed hyperbolic dependence of Kd2 on [Ca
2þ] is similar
to that reported for bovine FXa (17).
Amidolytic activity of FXa as a function of C6PS concentra-
tions and FXa concentration
Our results show that FXa dimerization alters mostly the kcat
of prothrombin proteolysis. A severe reduction in kcat can
reflect significant misalignment of substrate with the active
site. The active site could be occluded; the substrate might
not bind to the active site or could bind inappropriately to
an exosite, thereby causing misalignment at the active site;
or the active site could be altered in the arrangement of
key residues. To gain insight to these possibilities, we deter-
mined the amidolytic activity of FXa against the synthetic
substrate S-2765, which specifically binds to the FXa active
site independent of substrate binding exosites. The percent
of amidolytic activity of FXa relative to the activity in the
absence of C6PS is plotted in Fig. 5 as a function of
C6PS concentration (as described in Experimental Proce-
dures) for six different FXa concentrations. At low FXa
concentrations (up to 50 nM), C6PS decreased FXa amido-
lytic activity, as previously reported for monomer human
FXa (27). However, for high FXa concentrations(>50 nM), the amidolytic activity did not decrease. Thus,
dimerization alters or prevents the C6PS-induced changes
in the FXa active site that lower the amidolytic activity.
Our most notable observation, however, is that the active
site of the dimer is clearly available to the tripeptide
substrate and is successful in catalyzing its hydrolysis.
Thus, the active site is not occluded and its catalytic residues
are appropriately arranged to affect catalysis of the synthetic
substrate.
Effect of dimerization on FXa structure
Previous studies have shown that C6PS binding triggers
structural changes in monomeric FXa (14,17). Does dimer
formation trigger further structural changes in FXa? If so,
what kind?
Secondary structure by CD spectroscopy
Circular dichroism (CD) spectra were recorded in the range
260–190 nm for FXa in the absence and presence of 400 mM
C6PS and in the presence of 5 mMCa2þ (Fig. 6). Analysis of
these spectra using the software package CDPro (34) (anal-
ysis routines CDSSTR, CONTINLL, and SELCON3)
enabled the estimation of the secondary structure composi-
tion of FXa under these different conditions. The results ob-
tained in the absence of C6PS (open symbols) agree with
previous reports (mainly b-structure and a small amount of
a-helix) (14) and were the same at all three FXa concentra-
tion examined (150, 200, and 500 nM). Upon addition of
C6PS to 150 nM FXa (solid circles), the percent of a-helix
decreased as reported previously (14). For 200 nM (solid
triangles) and 500 nM (solid squares) FXa, the shape of
the spectrum changed dramatically. Although the data do
not extend to wavelengths low enough to accurately estimate
changes in b-structure or ‘‘other’’ structures, data obtained at
all but the highest factor Xa concentration (500 nM) do
suffice to obtain consistent estimates of a-helix from all three
algorithms in the CDPro package. The averages of theseBiophysical Journal 96(3) 974–986
980 Chattopadhyay et al.estimates obtained in the presence of C6PS are plotted in the
inset of Fig. 6 (solid symbols) versus the fraction of FXa as
dimer (obtained using Eq. 3 and the dimer dissociation
constant from Fig. 2). There was a dramatic decrease in
a-helix with dimer formation in the presence of C6PS, as
shown. Note that the point at 60% dimer was difficult to esti-
mate, both because there was so little helix and because the
OD of the sample was significant at 500 nM factor Xa. By
contrast, all three concentrations of FXa showed the same
helix content in the absence of C6PS (open symbols at 0%
dimer). The decrease in helix content corresponded to
a dramatic change in the shape of the CD spectra. Such
dramatic changes in CD spectra are usually attributed to
changes in tertiary (domain organization) or quaternary
structure (35,36). These data confirm a FXa structural
change (a decrease in a-helix) upon C6PS-induced dimeriza-
tion and suggest a significant rearrangement of either inter-
FIGURE 4 Effect of calcium concentration on FXa dimerization. (A)
Dependence of the initial rate of appearance of thrombin activity as a func-
tion of increasing concentration of FXa in buffer (50 mM Tris-HCl, 175 mM
NaCl, and 0.6% PEG) with 400 mM C6PS at 3 (open circles), 3.5 (solid
squares), 4 (open squares), 5 (solid triangles), and 6 (open triangles) mM
Ca2þ concentration. The curves through the data are hyperbolas, from which
we estimated dimer dissociation constants (Kd2). (B) Variation of the dimer
dissociation constant (Kd2) of human FXa with Ca
2þ concentration at
400 mMC6PS. Values obtained as described in A are shown as solid circles,
whereas values obtained using a full global analysis of proteolytic rates (Eqs.
1–3 as applied to data shown in Fig. 2 at different Ca2þ concentrations) are
shown as open triangles.Biophysical Journal 96(3) 974–986domain contacts within the protein or secondary structure
at the dimer interface.
Tertiary and/or quaternary structure changes detected by Lys
acetylation and MALDI- and nanoLC ESI-MS
Acetylation of lysine residues of FXa was performed under
four conditions (described in Experimental Procedures)
designed to distinguish changes due to Ca2þ binding,
C6PS binding, and dimer formation. Different lysine resi-
dues were found to be modified under the four different
conditions, which reveals clearly that conformational
changes take place in the protein upon Ca2þ binding, upon
C6PS binding, with an increase in Ca2þ concentration, and
FIGURE 5 Initial rate of amidolysis of synthetic substrate S-2765 as
a function of C6PS concentrations and at different FXa concentrations.
The rate was determined at 37C in buffer (containing 50 mM Tris,
175 mM NaCl, 0.6% PEG, and 5 mM Ca2þ), as described in Experimental
Procedures. The data are expressed as a percentage of the rate of S-2765
hydrolysis by FXa in the absence of C6PS and were analyzed according
to a previously described model for C6PS binding resulting in dimer forma-
tion (17), as summarized in Eq. 4 (Experimental Procedures). Rates are
plotted for increasing concentrations of C6PS and several FXa concentra-
tions: (A) human FXa at 5 nM (solid circles), 10 nM (open circles),
25 nM (solid inverted triangles), 50 nM (open triangles), 100 nM (solid
squares) and 200 nM (open squares); (B) bovine FXa at 5 nM (solid circles),
10 nM (solid squares), 25 nM (open circles), 50 nM (open triangles), 75 nM
(solid inverted triangles), and 100 nM (solid diamond). The data showed
that amidolytic activity of monomeric FXa decreased substantially (~70%)
in response to C6PS binding, whereas such a decrease was not observed
for the dimer.
Factor Xa Dimer Structure 981upon dimer formation. Based on this analysis, lysine residues
were categorized into different types: 1), residues accessible
to acetylation; 2), residues not accessible to acetylation and
observed unmodified in proteolytic peptides; and 3), residues
not observed at all. Category 3 residues do not appear in
digests because of the size of the proteolytic fragment or ioni-
zation efficiency of the fragment. Proteolysis takes place
under the same conditions no matter what conditions were
used for the initial acetylation. Thus, the fact that a residue
can be observed for one set of conditions and not for another
results from the fact that the proteolysis pattern is affected by
the acetylation of lysine side chains, since trypsin does not
recognize acetylated lysines. Thus, category 3 lysines provide
no structural insight. Category 1 residues are exposed to the
aqueous surrounding under the conditions of acetylation.
Category 2 residues are not exposed to the aqueous environ-
ment under the conditions of acetylation, but they still appear
in identifiable peptides. These two categories of lysines
provide us with structural insights.
There are three aspects of these results that we wish to
mention. First, and most relevant to this study, are changes
that accompany dimer formation. Based on our experiments,
we can take two paths to form a dimer. First, we add C6PS to
FXa in the presence of Ca2þ. C6PS binds to FXa in the pres-
ence of 3 mM Ca2þ but does not form significant dimer at
this low Ca2þ concentration. However, adding C6PS to
FXa in the presence of 5 mMCa2þ does trigger dimerization.
FIGURE 6 Change in secondary structure of FXa in the absence and pres-
ence of C6PS at monomeric and dimeric FXa concentrations. FXa was
examined at 24C at varying concentrations (150 nM (circles), 200 nM
(triangles), and 500 nM (squares)) in buffer (1.2 mM Tris, 150 mM
NaCl, and 5 mM CaCl2, pH 7.4) in the presence of 400 mM C6PS (solid
symbols) and absence of C6PS (open symbols). The optical density of
each sample was %0.1 at 200 nm (except for the 500 nM FXa, which had
an OD of 0.16), and all spectra were reproducible for different FXa samples
prepared on different days. (Inset) Variation of the percentage of a-helix
with the fraction of FXa present as dimer (from Eq. 3 and dimer dissociation
constant from Fig. 2). Points are presented for FXa at three concentrations in
the presence (solid symbols) and absence (open symbols show 0% dimer) of
C6PS.Thus, changes in acetylation that are the same in these two
processes do not reflect dimer formation, but changes that
differ between these two processes likely do. The results
for these two processes (Path A) are summarized in Table
S1 in the Supporting Material, where we use the Fung
numbering system (37). The second path (Path B) involves
increasing the Ca2þ concentration from 3 to 5 mM in the
absence and presence of 400 mM C6PS (Table S2). The
combination of observations from paths A and B demon-
strate that lysine 270 becomes inaccessible to acetylation
due to dimer formation. Lysine 414 went from being inacces-
sible to the aqueous environment in the monomer state
(independent of Ca2þ concentration) to being accessible to
acetylation in the dimer state. These results are summarized
in terms of an atomic model for FXa structure in Fig. 7 C.
We wish to focus next on changes associated with
increasing the Ca2þ concentration from 3 to 5 mM. These
changes are summarized in the first column of Table S2.
Increased Ca2þ binding leads to exposure of lysines 289,
420, and 427, all of which are on the bottom face of the cata-
lytic domain (see Fig. 7 A). On the opposite face of the cata-
lytic domain, we find that increased Ca2þ concentration
leads to burial of lysines 406 and 408. A single Ca2þ
(Fig. 7, light blue sphere) is located in the catalytic domain
and has interactions with residues in the sequence D250–
E260 (38). The Ca2þ binding site is linked to a Naþ (Fig. 7,
red sphere) binding region defined by residues W399–I411
(39) that includes lysines 406 and 408, which become buried
upon increasing the Ca2þ concentration.
Third, we consider the consequences of C6PS binding
under conditions that favor the monomer state (i.e., 3 mM
Ca2þ). These results are summarized in column 1 of Table
S1 and in Fig. 7 B. Lysine 242 becomes less accessible
and lysines 289, 351, and 420 become accessible to acetyla-
tion as a result of C6PS binding.
DISCUSSION
We showed previously that bovine factor Xa dimerizes upon
C6PS binding, but we did not know whether human factor
Xa forms a dimer, whether the dimer is active, or how the
dimer structure differs from that of the monomer (17). We
began this study to answer three questions: 1), Does human
FXa form a dimer in solution? 2), If so, is the dimer active or
does dimer formation block activity? and 3), Are structural
changes associated with dimer formation small enough that
we can think of the dimer structure in terms of the structure
of two monomers? Our results clearly demonstrate that
human FXa forms a dimer in solution in response to C6PS
binding and that the dimer is essentially inactive. It appears
that dimer formation does not occlude the active site, since
the dimer still had amidolytic activity against the synthetic
substrate S-2765. On the other hand, proteolytic activity
against prothrombin was enormously reduced, primarily
through a 107-fold decrease in kcat. Because the active siteBiophysical Journal 96(3) 974–986
982 Chattopadhyay et al.FIGURE 7 An atomic-resolution
FXa model for human FXa in the pres-
ence of 3 mM Ca2þ (25) is shown.
There are no crystallographic models
for whole factors Xa, and certainly
none that include information about
how these might interact with
a membrane. We felt that the model
developed by the Pedersen lab had the
best theoretical underpinnings, and Dr.
Pedersen kindly provided us with coor-
dinates for this model. This model is
based on a crystallographic model of
human GLA-domainless FXa (59) and
of the EGFN GLA region from the
factor VIIa-FXa-tissue factor complex
(60). This model is shown with a lyso-
phosphatidylserine molecule (green,
carbon; blue, nitrogen; red, oxygen;
and yellow, phosphorus) inserted
(Insight II and Pymol) using the coordi-
nates from the PT1 (bovine
prothrombin fragment 1)-Ca2þ-lyso-
phosphatidylserine complex (47). The
active site residues are colored black,
and light and heavy chains are colored
purple and yellow, respectively. Ca2þ
ions are aqua (aqua arrow) and the
Naþ ion is red (red arrow). (A–C) These
three views highlight lysine residues
whose exposure to acetylation, as deter-
mined by mass spectrometry, changes
(blue, becomes exposed; green,
becomes buried) upon (A) increasing
Ca2þ concentration from 3 to 5 mM,
(B) adding C6PS in the presence of
3 mM Ca2þ (nondimerization condi-
tions), and (C) adding C6PS in the pres-
ence of 5 mM Ca2þ (dimerization
conditions). (D–G) These views show
the two lysine residues whose exposure
to acetylation is changed during dimer
formation (K414 (blue arrow in G) and
K270 (green arrow in G)). (F) View ob-
tained by rotating the molecule until the
seven Ca2þ ions at the base of the GLA
domain were roughly in a plane, as
proposed previously (47). The Ca2þ
planarity was tested by rotating F about
the y axis by 90 to obtainG, which was
adjusted and rotated to obtain F, etc., until it was clear that these Ca2þ ions were in a common plane. A slice through a hypothetical PS-containing membrane
normal to the plane of the picture is shown to illustrate the arrangement of the Ca2þ plane and thus the molecule relative to a membrane.D and Ewere obtained
by rotation of F and G, respectively, about the x axis by 90 degrees clockwise.is not blocked from accessing small substrates, it is likely
that dimerization interferes with binding of the substrate to
exosites that are crucial for aligning the proper substrate
with the active site. This is reasonable, as a dimer interface
that included K270 would almost surely interfere with
substrate binding to the exosite identified to include residues
V262–H271 and D282–M296 (40) (see Fig. 7). Dimer formation
also causes rearrangements within the active site (Fig. 5) that
could also contribute to the decrease in kcat.Biophysical Journal 96(3) 974–986The results presented here provide insights into structural
changes associated with Ca2þ and C6PS binding to FXa and
with C6PS-induced dimerization. Because whole FXa has
yet to be crystallized, even in a C6PS-free form, atomic-reso-
lution information on these changes is not available. To illus-
trate our results in terms of an atomic-resolution FXa model,
we have adopted a model of human FXa in the presence of
Ca2þ (3 mM) (25) (Fig. 7). We begin with the effects of
C6PS binding under conditions that do not favor dimer
Factor Xa Dimer Structure 983formation (3mMCa2þ). Twomolecules of C6PS bind to FXa,
one to a site involving the EGFN linked to the GLA domain
that regulates activity and one to a Ca2þ-and-Naþ-requiring
site in the catalytic domain (14). These two sites are linked,
with the site in the regulatory EGF region likely occupied first
and then triggering binding to the second site (16). This second
site is probably related to a quaternary amine site that likely
defines a protein-binding region and is linked to Naþ binding
(14,41). The four lysines affected by addition of 400mMC6PS
are shown in Fig. 7 B. Lysine 351 is part of a Va binding site
identified by mutational study (42). Lysine 242 is adjacent to
H236, one of the residues that form the FXa catalytic triad
(H236, D282, and S379) shown in black in Fig. 7. Lysine 420
is located close to a proposed factor Va binding region,
A404–F418 (44), and part of a substrate exosite A417–K427
(45). Also, K420 belongs to a peptide V415–R429 proposed to
interfere with II binding (44). Both K420 and K427, residing
in theA417–K427 region, also become exposed upon increasing
Ca2þ (Fig. 7 A). Since 400 mMC6PS saturates the lipid regu-
latory site in the EGF region (14), it appears that binding of
C6PS to the regulatory site exposes a lysine in one substrate
exosite (K420), buries a lysine (K242) directly adjacent to the
active site (H236), and exposes a lysine in an FVa binding
region (K351). This is sensible, since binding of C6PS to
FXa monomer increases the kcat and slightly decreases the
KM of FXa during prothrombin activation (16) and enhances
binding of FVa to FXa ~1000-fold (46). This demonstrates
remarkable cooperativity between Naþ, Ca2þ, C6PS,
substrate, and FVa binding, painting the catalytic domain as
a precisely tuned, multifaceted structure sensitive to events
far from the active site (C6PS binding to the EGF-GLA).
We turn now to changes in lysines associated with C6PS-
induced dimerization, which occurs at 5 mM Ca2þ. Fig. 7 C
shows that under this treatment K270 becomes inaccessible
and K414 accessible. We note that, although increased Ca2þ
concentration and C6PS addition at 3 mM Ca2þ change the
exposure of five and four lysines, respectively, only two
lysines are changed upon dimer formation. The exposed
residue, K414, is in a region previously identified as involved
in Va binding (44) and is linked to a substrate binding site
(44). Since neither increasing Ca2þ from 3 to 5 mM nor add-
ing C6PS in the presence of 3mMCa2þ exposed K414, it must
be that dimerization triggers an FXa conformation in which
K414 is exposed to the aqueous medium. It is interesting that
K414 appears exposed in the particular conformation shown
in Fig. 7 (based on x-ray data), but our mass spectrometry
results show it as buried except in the dimer.
Interpretation of the change in K270 is less straightforward.
This residue also is not changed upon increasing Ca2þ
concentration and adding C6PS at 3 mM Ca2þ (Table S1
and Table S2). Since it becomes inaccessible upon dimer
formation, one possibility is that it is in the dimer interface.
However, it could also be that dimer formation triggers
a conformational change that removes K270 from water expo-
sure. Fig. 7, D–G, shows several views of FXa arranged sothat seven Ca2þ ions believed to reside at the membrane
surface (47) are in a plane. Constraining these Ca2þ ions to
the membrane surface requires that FXa molecules are side-
to-side in the dimer. If K270 is buried in the dimer interface,
it is difficult to imagine how the conformation of FXa shown
in Fig. 7 (25) could form a side-to-side dimer. It could be that
the solution dimer does not have the same arrangement of FXa
molecules that might exist in a membrane-bound dimer, i.e.,
the solution dimer may be head-to-head, whereas the
membrane dimer may be side-to-side. It is not possible, on
the basis of our data alone, to distinguish between these possi-
bilities. However, several observations, discussed next, favor
the dimer being side-to-side (as it would be on a membrane)
and, at the same time, K270 being in the dimer interface.
First, preliminary data indicate that an inactive dimer also
forms on a membrane (T. Koklic and R. Majumder, unpub-
lished observations). Unless this dimer is fundamentally
different from the inactive solution dimer, both would need
to be side-to-side. Second, FXa dimer formation also interferes
with FVa binding to FXa (R. Majumder and B. R. Lentz,
unpublished observations). K270 is part of a synthetic peptide
motif (H263–K276) previously shown to interfere with FVa
binding (48). Since the FVa binding region of FXa is now
widely believed to be in the Y367–D373 loop (49) and/or the
Y344–K351 helix (10,43), it is likely that peptide (H263–K276)-
based inhibition of FVa binding is a secondary effect caused
by H263–K276 (including K270) being in another protein recog-
nition region that communicates with the FVa binding region.
Sinceweknow that dimer formation lowers kcat substantially, it
is reasonable to conjecture that K270 might be in a substrate
recognition region. Third, if K270 is in the dimer interface,
the conformation of FXa on the membrane or in the dimer
must be very different from that shown in Fig. 7. Binding
data obtained by elipsometry suggest that the conformation
of FXa in the dimer may be very different from the monomer
structure shown in Fig. 7. These data show twice as many
FXa molecules bound to a bilayer surface as factor X, suggest-
ing that FXa occupies half the surface area of factorX (50). The
binding stoichiometries obtained from this study were 26 and
53 lipids/protein in the outer bilayer leaflet for FXa and FX,
respectively. The former agrees quite well with the value of
~26 obtained for human FXa binding to the outer monolayer
of 23 nm 20% PS vesicles (51). Given that the catalytic
‘‘head’’ of FXa has a rotationally averaged diameter (about
the FXa long axis) of 40–45 A˚ and that the area/lipid molecule
in a bilayer is ~60–70 A˚2/lipid, depending on the lipid and the
method of estimation (52), we would estimate that the stoichi-
ometry of a cylindrical FXa perpendicular to a membrane
would be 23–33 lipids/FXa. This is in reasonably good agree-
ment with the experimentally determined values of 26.
However, in Fig. 7, F andG, we show that the FXa conforma-
tion used must be at an angle to the plane of the bilayer if its
membrane-binding GLA-domain Ca2þ ions are constrained
to be coplanar with the membrane. From this model, we
estimate that the rotationally averaged (about an axisBiophysical Journal 96(3) 974–986
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close to 60 A˚. Based on this estimation, the stoichiometry of
FXa binding should be ~50 lipids/FXa, approximately what
has been reported for FX (50). This suggests that FX and
FXa have different membrane-associated conformations and
that themembrane conformation of FX is similar to that shown
in Fig. 7 for FXa. Consistent with this, the Pedersen group’s
model of FXa is only slightly different from their model of
FX (25). At any rate, binding stoichiometries support the
FXa conformation on a membrane being quite different from
that shown in Fig. 7. Finally, the Pedersenmodel of FXa based
on x-ray structures (25) puts the active site 89 A˚ from the plane
of Ca2þ ions that define the membrane-protein interface,
whereas fluorescence resonance energy transfer puts this
distance at 61 A˚ (26), again suggesting that the membrane-
or PS-bound conformation is not that shown in Fig. 7. This is
quite reasonable, since membrane- or C6PS-induced confor-
mational rearrangements between domains within
prothrombin have been reported ((23,54) and S. Sen, R. Chat-
topadhyay, M. Banerjee, R. Majumder, C. Zhow, and B. R.
Lentz; unpublished observations), and prothrombin is structur-
ally similar to FX. Such conformational changes could well
change the orientation of the catalytic domain relative to the
EGFpair, aswell as the relationship between theEGFdomains,
so that K270 could be buried in a side-to-side dimer interface.
If this interpretation of our results is correct, it would not
be possible to examine the structure of FXa dimer without
achieving a PS-activated conformation. Since FVa also
undergoes conformational changes and changes in interdo-
main interactions (55) that are responsible for tight binding
to FXa (28,46,56), it is likely that the structure of the FXa-
FVa complex can also not be modeled using other than struc-
tures of PS-activated forms of the individual proteins, which
to date are not available.
What are the physiological implications of our observation
that human FXa forms inactive dimers under the influence of
phosphatidylserine? The strength of the dimer interaction is
strongly Ca2þ-concentration-dependent, such that significant
dimer forms in solution only at or above 5 mM Ca2þ. The
Ca2þ concentration is 1–1.5mM in plasma (57,58), well below
the Ca2þ concentrations shown here that are needed to trigger
dimer formation.However, FXadimerswouldnot form in solu-
tion in plasma in any case, since soluble PSmust bind to trigger
dimer formation, and short chain phospholipids do not occur
naturally. FXa binds to PS in membranes released by activated
platelets in the platelet plug, within which Ca2þ concentration
increases to 3–5 mM (58). Of course, it takes a much smaller
free energy of interaction to bring proteins into association on
a membrane surface than in solution simply because there is
less entropy loss in the surface-mediated process.We conclude
that FXa dimerization could be a significant Ca2þ-regulatory
mechanism physiologically, although we will need to investi-
gate FXa behavior on a membrane surface to better judge this
possibility. These studies are well underway, and thus far,
results demonstrate formation of an inactive FXa dimer onBiophysical Journal 96(3) 974–986amembrane (T. Koklic, R.Majumder, andG.Weinreb, unpub-
lished observations), as reported here for FXa in solution.
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